Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Don't miss Jupiter shining close to the waning gibbous moon on Dec. 7 - 2It Looks Like a Tiny, Fluffy Dragon, But It's Really a Bird. Meet the Great Eared Nightjar
- 3Carrefour becomes first European retailer to offer shopping on ChatGPT
- 4There was a bit of toilet trouble on NASA's Artemis 2 mission to the moon
- 5The Appearance of Experience: Embracing the Reduced Portage Horse
- The Best 15 Applications for Efficiency and Association
- Video of clashes over purported conscription orders misrepresented as anti-war protest in Israel
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- Dominating the Mastercard Endorsement Cycle: Six Fundamental Stages
- Oil rises above $115 and Asia stocks slide as Iran war escalates
- As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico
- Striking American and European television Projects: A Survey
- Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
- Nearly 16,000 New York City nurses prepare to strike as contract talks stall
